Islet transplantation in patients with diabetes mellitus: Choice of immunosuppression

BioDrugs

Volumn 18, Issue 5, 2004, Pages 315-328

  Nanji, Sulaiman A ^a   Shapiro, A M James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIOXIDANT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METFORMIN; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; ALLOIMMUNITY; AUTOIMMUNITY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; HYPOINSULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; POSTTRANSPLANTATION LYMPHOMA; PRIORITY JOURNAL; REVIEW; SEPSIS;

CANADA; CLINICAL PROTOCOLS; CLINICAL TRIALS; DIABETES MELLITUS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 6044240730     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418050-00004     Document Type: Review

References (158)

1. Williams P. Notes on diabetes treated with extract and by grafts of sheep's pancreas. BMJ 1894; 2: 1303-4
2. Banting F. Extract from Banting's notebook 2am October 31st. Canada: Academy of Medicine notebook, Archives of Toronto University, 1920
3. Bliss M. The discovery of insulin. Toronto: McClelland and Stewart Limited, 1982
4. Lacy P, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35-9
5. Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplantation: a preliminary report. Transplant Proc 1977; 9 (1): 233-6
6. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37 (4): 413-20
7. Robertson GS, Chadwick DR, Contractor H, et al. The optimization of large-scale density gradient isolation of human islets. Acta Diabetol 1993; 30 (2): 93-8
8. Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997; 46 (7): 1120-3
9. Brendel M, Hering B, Schulz A, et al. International islet transplant registry report. University of Giessen, Germany; 1999. Newsletter No. 8
10. Boker A, Rothenberg L, Hernandez C, et al. Human islet transplantation: update. World J Surg 2001; 25 (4): 481-6
11. Hering B, Ricordi C. Islet transplantation for patients with type 1 diabetes: results, research priorities, and reasons for optimism. Graft 1999; 2 (1): 12-27
12. Kaufman DB, Morel P, Condie R, et al. Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function. Transplantation 1991; 51 (1): 37-42
13. Rilo HL, Carroll PB, Zeng YJ, et al. Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Transplantation 1994; 57 (2): 181-7
14. Zeng Y, Ricordi C, Lendoire J, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery 1993; 113 (1): 98-102
15. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343 (4): 230-8
16. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003; 362 (9391): 1242
17. Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977; 32 (6): 1017-25
18. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; II (8151): 1033-6
19. Halloran PF, Madrenas J. The mechanism of action of cyclosporine: a perspective for the 90's. Clin Biochem 1991; 24 (1): 3-7
20. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357 (6380): 695-7
21. Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994; 369 (6480): 497-502
22. Gunnarsson R, Klintmalm G, Lundgren G, et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 1984; 16 (3): 709-12
23. Andersson A, Borg H, Hallberg A, et al. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984; 27 Suppl. 1: 66-9
24. Robertson RP. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 1986; 35 (9): 1016-9
25. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic β-cells. Diabetes 1986; 35 (9): 1049-52
26. Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29 (8): 489-94
27. Helmchen U, Schmidt WE, Siegel EG, et al. Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia 1984; 27 (3): 416-8
28. Eun HM, Pak CY, Kim CJ, et al. Role of cyclosporin A in macromolecular synthesis of beta-cells. Diabetes 1987; 36 (8): 952-8
29. Garvin PJ, Niehoff M, Staggenborg J. Cyclosporine's effect on canine pancreatic endocrine function. Transplantation 1988; 45 (6): 1027-31
30. Kneteman NM, Marchetti P, Tordjman K, et al. Effects of cyclosporine on insulin secretion and insulin sensitivity in dogs with intrasplenic islet autotransplants. Surgery 1992; 111 (4): 430-7
31. Alejandro R, Feldman EC, Bloom AD, et al. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38 (6): 698-703
32. Jindal RM. Posttransplant diabetes mellitus: a review. Transplantation 1994; 58 (12): 1289-98
33. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70 (11 Suppl.): SS58-63
34. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44 (3): 376-81
35. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994; 43 (4): 593-8
36. Ziel FH, Venkatesan N, Davidson MB. Glucose transport is rate limiting for skeletal muscle glucose metabolism in normal and STZ-induced diabetic rats. Diabetes 1988; 37 (7): 885-90
37. Venkatesan N, Davidson MB, Hutchinson A. Possible role for the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. Metabolism 1987; 36 (9): 883-91
38. Rizza RA, Mandarine LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982; 54 (1): 131-8
39. Munck A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance. Perspect Biol Med 1971; 14 (2): 265-9
40. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44 (6): 729-33
41. Ost L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation 1987; 44 (4): 533-5
42. Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992; 53 (2): 407-14
43. Maffi P, Bertuzzi F, Guiducci D, et al. Per and peri-operative management influences the clinical outcome of islet transplantation. Am J Transplant 2001; 1 (1 Suppl. 1): 181
44. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31 (5): 335-40
45. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17 (6): 660-5
46. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19 (1 Pt 2): 1284-6
47. Yoshimura N, Matsui S, Hamashima T, et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro: I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 1989; 47 (2): 351-6
48. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; II (8670): 1000-4
49. Fung J, Todo S, Abu-Elmagd K, et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc 1993; 25 (1 Pt 2): 1130
50. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344 (8920): 423-8
51. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66 (4): 493-9
52. Rilo HL, Carroll PB, Tzakis A, et al. Insulin independence for 58 months following pancreatic islet cell transplantation in a patient undergoing upper abdominal exenteration. Transplant Proc 1995; 27 (6): 3164-5
53. Carroll PB, Rilo HL, Aiejandro R, et al. Long-term (> 3-year) insulin independence in a patient with pancreatic islet cell transplantation following upper abdominal exenteration and liver replacement for fibrolamellar hepatocellular carcinoma. Transplantation 1995; 59 (6): 875-9
54. Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51 (1): 76-85
55. Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation 1993; 56 (6): 1293-8
56. Shibata S, Matsumoto S, Sageshima J, et al. Temporary treatment with sirolimus and low-trough cyclosporine prevents acute islet allograft rejection, and combination with starch-conjugated deferoxamine promotes islet engraftment in the preclinical pig model. Transplant Proc 2001; 33 (1-2): 509
57. Kahan BD. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation. Transplant Proc 1995; 27 (1): 33-6
58. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64 (12): 1853-6
59. Chen H, Qi S, Xu D, et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. Transplant Proc 1998; 30 (6): 2579-81
60. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355 (9201): 376-7
61. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23): 1773-80
62. Tkaczuk J, Milford E, Yu C, et al. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab. Transplant Proc 2001; 33 (1-2): 212-3
63. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322 (17): 1175-82
64. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991; 23(1 Pt 2): 1066-7
65. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999; 67 (1): 110-5
66. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action: double therapy and the Triple Therapy Study Groups. Transplant Proc 1998; 30 (5): 2155-8
67. Ekberg H, Backman L, Tufveson G, et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13 (2): 151-9
68. Stratta RJ, Taylor RJ, Castaldo P, et al. Preliminary experience with FK 506 in pancreas transplant recipients. Transplant Proc 1995; 27 (6): 3024
69. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001; 233 (4): 463-501
70. Wohlrab J, Fischer M, Taube KM, et al. Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol 2001; 144 (1): 209-10
71. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51 (7): 2148-57
72. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63 (1): 1-6
73. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65 (9): 1159-69
74. Thomas JM, Contreras JL, Jiang XL, et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999; 68 (11): 1660-73
75. Contreras JL, Eckhoff DE, Cartner S, et al. Long-term functional islet mass and metabolic function after xenoislet transplantation in primates. Transplantation 2000; 69 (2): 195-201
76. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999; 67 (6): 846-54
77. Thomas JM, Contreras JL, Smyth CA, et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes 2001; 50 (6): 1227-36
78. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158 (6): 2947-54
79. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346 (22): 1692-8
80. Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003; 111 (3): 409-18
81. Hering BJ, Matsumoto I, Sawada T, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation 2002; 74 (12): 1813-6
82. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30 (4): 424-33
83. Lockwood CM, Thiru S, Isaacs JD, et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341 (8861): 1620-2
84. Coles AJ, Wing MG, Compston DA. Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy. Mult Scler 1998; 4 (3): 232-8
85. Killick SB, Marsh JC, Hale G, et al. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 1997; 97 (2): 306-8
86. Lim SH, Hale G, Marcus RE, et al. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993; 84 (3): 542-4
87. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68 (10): 1613-6
88. Calne R, Moffatt SD, Friend PJ, et al. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi 2000; 101 (3): 301-6
89. Knechtle SJ, Pirsch JD, Fechner JJH, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3 (6): 722-30
90. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356 (6370): 607-9
91. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58
92. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248 (4961): 1349-56
93. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159 (11): 5187-91
94. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999; 96 (14): 8132-7
95. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48 (7): 1473-81
96. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162 (8): 4983-90
97. Knosalla C, Gollackner B, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism revisted. Transplantation 2002; 74 (3): 416-7
98. Buhler L, Alwayn IP, Appel JZ, et al. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 2001; 71 (3): 491
99. Garlichs CD, Geis T, Goppelt-Struebe M, et al. Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. Atherosclerosis 2002; 163 (1): 9-16
100. Szabolcs MJ, Cannon PJ, Thienel U, et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch 2000; 437 (2): 149-59
101. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9 (5): 641-7
102. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74 (7): 933-40
103. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51 (2): 265-70
104. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2 (3): 203-9
105. Nanji S, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7R-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004; 4 (4): 526-36
106. Nakamura Y, Yasunami Y, Satoh M, et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. Transplantation 2003; 75 (8): 1115-8
107. Gao W, Demirci G, Li XC. Negative T cell costimulation and islet tolerance. Diabetes Metab Res Rev 2003; 19 (3): 179-85
108. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003; 76 (6): 994-9
109. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166 (1): 322-9
110. Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 1998; 95 (7): 3821-6
111. Auersvald LA, Rothstein DM, Oliveira SC, et al. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation 1997; 63 (9): 1355-8
112. Auersvald LA, Rothstein DM, Oliveira SC, et al. Anti-CD45RB treatment prolongs islet allograft survival in mice. Transplant Proc 1997; 29 (1-2): 771
113. Shapiro ME, Liu M. Prolongation of islet allograft survival by anti-CD45 antibody pretreatment. Transplant Proc 1995; 27 (1): 613-4
114. Molano RD, Berney T, Pileggi A, et al. Prolonged survival of allogeneic islet grafts in NOD mice treated with a combination of anti-CD45RB and anti-CD154 antibodies. Transplant Proc 2001; 33 (1-2): 248-9
115. Molano RD, Pileggi A, Berney T, et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 2003; 52 (4): 957-64
116. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5 (6): 686-93
117. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5 (11): 1298-302
118. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5 (11): 1303-7
119. Nelson PJ, Krensky AM. Chemokines and allograft rejection: narrowing the list of suspects. Transplantation 2001; 72 (7): 1195-7
120. Hancock WW, Gao W, Faia KL, et al. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12 (5): 511-6
121. Abdi R, Means TK, Luster AD. Chemokines in islet allograft rejection. Diabetes Metab Res Rev 2003; 19 (3): 186-90
122. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/ CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171 (12): 6929-35
123. Abdi R, Smith RN, Makhlouf L, et al. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002; 51 (8): 2489-95
124. Baker MS, Chen X, Rotramel AR, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003; 134 (2): 126-33
125. Brinkmann V, Pinschewer D, Chiba K, et al. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000; 21 (2): 49-52
126. Brinkmann V, Pinschewer DD, Feng L, et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72 (5): 764-9
127. Brinkmann V, Chen S, Feng L, et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001; 33 (1-2): 530-1
128. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms: I. prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28 (2): 1056-9
129. Xu M, Pirenne J, Antoniou EA, et al. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl Int 1998; 11 (4): 288-94
130. Stepkowski SM, Wang M, Qu X, et al. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival. Transplant Proc 1998; 30 (5): 2214-6
131. Hoshino Y, Suzuki C, Ohtsuki M, et al. FTY720, a novel immunosuppressant possessing unique mechanisms: II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 1996; 28 (2): 1060-1
132. Schuurman HJ, Menninger K, Audet M, et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74 (7): 951-60
133. Fu F, Hu S, Li S, et al. FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. Transplant Proc 2001; 33 (1-2): 672-3
134. Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73 (9): 1425-30
135. Wijkstrom M, Kenyon NS, Kirchhof N, et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77 (6): 827-35
136. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002; 74 (12): 1684-6
137. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105 (2): 125-33
138. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360 (9350): 2039-45
139. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51 (6): 1779-84
140. Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004; 77 (5): 741-7
141. Farney AC, Xenos E, Sutherland DE, et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993; 25 (1 Pt 2): 865-6
142. Brandhorst D, Brandhorst H, Zwolinski A, et al. High-dosed nicotinamide decreases early graft failure after pig to nude rat intraportal islet transplantation. Transplantation 2002; 73 (1): 74-9
143. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43 (11): 1337-45
144. Gysemans C, Van Etten E, Overbergh L, et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 2002; 128 (2): 213-20
145. Riachy R, Vandewalle B, Belaich S, et al. Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. J Endocrinol 2001; 169 (1): 161-8
146. Contreras JL, Smyth CA, Bilbao G, et al. Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation 2002; 74 (8): 1063-9
147. Arita S, Nagai T, Ochiai M, et al. Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin. Transplantation 2002; 73 (1): 7-12
148. Auchincloss H. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001; 1 (1): 6-12
149. Adams AB, Shirasugi N, Jones TR, et al. Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003; 3 (7): 895-901
150. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74 (10): 1405-9
151. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114 (11): 954-5
152. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68 (4): 480-4
153. Sykes M, Spitzer TR. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 2002; 110: 79-99
154. Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95 (6): 2175-82
155. Li H, Inverardi L, Molano RD, et al. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts. Transplantation 2003; 75 (7): 966-70
156. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361 (9368): 1502-10
157. Oike F, Yokoi A, Nishimura E, et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc 2002; 34 (5): 1521
158. Tanaka K, Kiuchi T. Living-donor liver transplantation in the new decade: perspective from the twentieth to the twenty-first century. J Hepatobiliary Pancreat Surg 2002; 9 (2): 218-22